Data Insights

Uzatresgene autoleucel by Adaptimmune Therapeutics for Ovarian Cancer: Likelihood of Approval

Uzatresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Ovarian Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Uzatresgene Autoleucel in Ovarian Cancer

Data Insights

Afamitresgene autoleucel by Adaptimmune Therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma): Likelihood of Approval

Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)....

Likelihood of Approval and Phase Transition Success Rate Model - Afamitresgene Autoleucel in Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)

Data Insights

Afamitresgene autoleucel by Adaptimmune Therapeutics for Neuroblastoma: Likelihood of Approval

Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Neuroblastoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Afamitresgene Autoleucel in Neuroblastoma

Data Insights

Afamitresgene autoleucel by Adaptimmune Therapeutics for Osteosarcoma: Likelihood of Approval

Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Osteosarcoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Afamitresgene Autoleucel in Osteosarcoma

Data Insights

Letetresgene autoleucel by Adaptimmune Therapeutics for Synovial Sarcoma: Likelihood of Approval

Letetresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Synovial Sarcoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Letetresgene Autoleucel in Synovial Sarcoma

Data Insights

Letetresgene autoleucel by Adaptimmune Therapeutics for Round Cell Liposarcoma: Likelihood of Approval

Letetresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Round Cell Liposarcoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Letetresgene Autoleucel in Round Cell Liposarcoma

Data Insights

Letetresgene autoleucel by Adaptimmune Therapeutics for Myxoid Liposarcoma: Likelihood of Approval

Letetresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Myxoid Liposarcoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Letetresgene Autoleucel in Myxoid Liposarcoma

Data Insights

Afamitresgene autoleucel by Adaptimmune Therapeutics for Synovial Sarcoma: Likelihood of Approval

Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Pre-Registration for Synovial Sarcoma. According to GlobalData, Pre-Registration...

Likelihood of Approval and Phase Transition Success Rate Model - Afamitresgene Autoleucel in Synovial Sarcoma

Data Insights

Risk adjusted net present value: What is the current valuation of Adaptimmune Therapeutics's Afamitresgene autoleucel?

Afamitresgene autoleucel is a gene-modified cell therapy commercialized by Adaptimmune Therapeutics, with a leading Pre-Registration program in Synovial Sarcoma. According...

Net Present Value Model: Adaptimmune Therapeutics Plc's Afamitresgene autoleucel

Data Insights

Risk adjusted net present value: What is the current valuation of Adaptimmune Therapeutics's Afamitresgene autoleucel?

Afamitresgene autoleucel is a gene-modified cell therapy commercialized by Adaptimmune Therapeutics, with a leading Pre-Registration program in Synovial Sarcoma. According...

Net Present Value Model: Adaptimmune Therapeutics Plc's Afamitresgene autoleucel